Sugi Predict

Sugi Predict / Targets / KDM8

KDM8

Bifunctional peptidase and arginyl-hydroxylase JMJD5 · Q8N371 · KDM8 on Sugi Atlas →

10,882 patent compounds predicted against KDM8, 6,270 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL547943 SCHEMBL547943 0.68 11/20
SCHEMBL1171098 SCHEMBL1171098 0.67 11/20
SCHEMBL517935 SCHEMBL517935 0.55 11/20
SCHEMBL686861 SCHEMBL686861 0.49 6/20
SCHEMBL1002512 SCHEMBL1002512 0.52 5/20
SCHEMBL1243693 SCHEMBL1243693 0.50 5/20
SCHEMBL1397838 SCHEMBL1397838 0.39 5/20
SCHEMBL644769 SCHEMBL644769 0.68 4/20
Enfenamic Acid Enfenamic Acid (SCHEMBL25191) 0.60 4/20
SCHEMBL1116010 SCHEMBL1116010 0.57 4/20
SCHEMBL870804 SCHEMBL870804 0.55 4/20
SCHEMBL231979 SCHEMBL231979 0.61 3/20
SCHEMBL155043 SCHEMBL155043 0.46 3/20
Water Water (SCHEMBL1201320) 0.44 3/20
SCHEMBL924382 SCHEMBL924382 0.41 3/20
SCHEMBL844422 SCHEMBL844422 0.40 3/20
SCHEMBL1533915 SCHEMBL1533915 0.63 2/20
SCHEMBL65841 SCHEMBL65841 0.63 2/20
SCHEMBL163637 SCHEMBL163637 0.63 2/20
SCHEMBL1505239 SCHEMBL1505239 0.61 2/20

Clinical trials — most relevant to KDM8 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
The Clinical Value of the Nitric Oxide System Components in Asthma and COPD nanUNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Mechanisms of Immune Deficiency nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
Evaluation of Lysine-Specific Demethylase 1 nanWITHDRAWN
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a KDM8 binder may also engage these)

ProteinNameSimilarity
Q9CXT6 — 1.000 Q9CXT6 →
Q1JP61 — 0.999 Q1JP61 →
Q497B8 — 0.997 Q497B8 →
B5XF11 — 0.973 B5XF11 →
A8E534 — 0.970 A8E534 →
Q14CH1 — 0.966 Q14CH1 →
Q96EN8 — 0.965 Q96EN8 →
B2GUS6 — 0.963 B2GUS6 →
Q9N0E7 — 0.961 Q9N0E7 →
Q8BK58 — 0.960 Q8BK58 →
D3ZRW8 — 0.957 D3ZRW8 →
Q9NVF9 — 0.957 Q9NVF9 →
Q7TQC5 — 0.957 Q7TQC5 →
P61797 — 0.956 P61797 →
A7MCT6 — 0.956 A7MCT6 →
Q9BGQ0 — 0.956 Q9BGQ0 →
Q7Z2E3 — 0.956 Q7Z2E3 →
COMT Catechol O-methyltransferase 0.955 landscape →
Q7YRZ2 — 0.955 Q7YRZ2 →
Q7YRZ1 — 0.955 Q7YRZ1 →
HLCS Biotin--protein ligase 0.955 landscape →
Q920N2 — 0.955 Q920N2 →
O54783 — 0.955 O54783 →
Q80WC9 — 0.954 Q80WC9 →
Q8BNV1 — 0.954 Q8BNV1 →
Q496Y0 — 0.954 Q496Y0 →
O55229 — 0.953 O55229 →
Q9HBU6 — 0.953 Q9HBU6 →
Q5H879 — 0.953 Q5H879 →
Q5BKC6 — 0.953 Q5BKC6 →